Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016

Published by Global Markets Direct on 30th December 2016 | Ref: 204901 | This Report Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Relapsing Multiple Sclerosis – Pipeline Review, H2 2016, provides an overview of the Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline landscape.

Progressive-relapsing multiple sclerosis (PRMS) refers to a pattern of relapses within primary-progressive MS (PPMS). Signs of PRMS include muscle spasms, weak muscles, dizziness, chronic pain and vision changes. Risk factors include age, family history, autoimmune diseases and smoking. Treatment includes immunosuppressant drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Relapsing Multiple Sclerosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Relapsing Multiple Sclerosis (PRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 3 respectively.

Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Relapsing Multiple Sclerosis (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Progressive Relapsing Multiple Sclerosis (PRMS) Overview 6

Therapeutics Development 7

Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Overview 7

Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Development by Companies 8

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Development by Companies 11

Progressive Relapsing Multiple Sclerosis (PRMS) - Companies Involved in Therapeutics Development 12

Cognosci Inc 12

Genzyme Corp 13

MedImmune LLC 14

VivaCell Biotechnology Espana SL 15

Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

COG-112 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

COG-133 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

GZ-402668 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

inebilizumab - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

VCE-0032 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects 32

Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products 33

Appendix 34

Methodology 34

Coverage 34

Secondary Research 34

Primary Research 34

Expert Panel Validation 34

Contact Us 34

Disclaimer 35

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

204901 | GMDHC8884IDB

Number of Pages

35

Report Format

PDF

This report is published by Global Markets Direct

Download Free Report Summary PDF

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.